Pharmacologic prevention of osteoporotic fractures

Osteoporosis is characterized by low bone mineral density and a deterioration in the microarchitecture of bone that increases its susceptibility to fracture. The World Health Organization defines osteoporosis as a bone mineral density that is 2.5 standard deviations or more below the reference mean...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American family physician 2004-10, Vol.70 (7), p.1293-1300
1. Verfasser: Zizic, Thomas M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1300
container_issue 7
container_start_page 1293
container_title American family physician
container_volume 70
creator Zizic, Thomas M
description Osteoporosis is characterized by low bone mineral density and a deterioration in the microarchitecture of bone that increases its susceptibility to fracture. The World Health Organization defines osteoporosis as a bone mineral density that is 2.5 standard deviations or more below the reference mean for healthy, young white women. The prevalence of osteoporosis in black women is one half that in white and Hispanic women. In white women 50 years and older, the risk of osteoporotic fracture is nearly 40 percent over their remaining lifetime. Of the drugs that have been approved for the prevention or treatment of osteoporosis, the bisphosphonates (risedronate and alendronate) are most effective in reducing the risk of vertebral and nonvertebral fractures. Risedronate has been shown to reduce fracture risk within one year in postmenopausal women with osteoporosis and in patients with glucocorticoid-induced osteoporosis. Hormone therapy reduces fracture risk, but the benefits may not outweigh the reported risks. Teriparatide, a recombinant human parathyroid hormone, reduces the risk of new fractures and is indicated for use in patients with severe osteoporosis. Raloxifene has been shown to lower the incidence of vertebral fractures in women with osteoporosis. Salmon calcitonin is reserved for use in patients who cannot tolerate bisphosphonates or hormone therapy.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67018947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>730025501</sourcerecordid><originalsourceid>FETCH-LOGICAL-p234t-27546176a47881257802d84d5597cef2f168738c44b81df75e181988a1c3f56f3</originalsourceid><addsrcrecordid>eNpdkE1LxDAYhHNQ3HX1L8jiwVsh33l7lMWPhQU9KHgr2TTRLm3fmqSC_96A68XTMMzDMMwJWVJKeQUC3hbkPKVDsUax-owsmFIUlKRLwp8_bByswx7fO7eeov_yY-5wXGNYY8oeJ4yYSxSidXmOPl2Q02D75C-PuiKv93cvm8dq9_Sw3dzuqokLmStulNTMaCsNAOPKAOUtyFap2jgfeGAajAAn5R5YG4zyDFgNYJkTQekgVuTmt3eK-Dn7lJuhS873vR09zqnRhjKopSng9T_wgHMcy7amLOFKS00LdHWE5v3g22aK3WDjd_N3hfgBfrVXfQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>234256460</pqid></control><display><type>article</type><title>Pharmacologic prevention of osteoporotic fractures</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Zizic, Thomas M</creator><creatorcontrib>Zizic, Thomas M</creatorcontrib><description>Osteoporosis is characterized by low bone mineral density and a deterioration in the microarchitecture of bone that increases its susceptibility to fracture. The World Health Organization defines osteoporosis as a bone mineral density that is 2.5 standard deviations or more below the reference mean for healthy, young white women. The prevalence of osteoporosis in black women is one half that in white and Hispanic women. In white women 50 years and older, the risk of osteoporotic fracture is nearly 40 percent over their remaining lifetime. Of the drugs that have been approved for the prevention or treatment of osteoporosis, the bisphosphonates (risedronate and alendronate) are most effective in reducing the risk of vertebral and nonvertebral fractures. Risedronate has been shown to reduce fracture risk within one year in postmenopausal women with osteoporosis and in patients with glucocorticoid-induced osteoporosis. Hormone therapy reduces fracture risk, but the benefits may not outweigh the reported risks. Teriparatide, a recombinant human parathyroid hormone, reduces the risk of new fractures and is indicated for use in patients with severe osteoporosis. Raloxifene has been shown to lower the incidence of vertebral fractures in women with osteoporosis. Salmon calcitonin is reserved for use in patients who cannot tolerate bisphosphonates or hormone therapy.</description><identifier>ISSN: 0002-838X</identifier><identifier>PMID: 15508540</identifier><identifier>CODEN: AFPYBF</identifier><language>eng</language><publisher>United States: American Academy of Family Physicians</publisher><subject>Aged ; Alendronate - administration &amp; dosage ; Alendronate - therapeutic use ; Bone Density - drug effects ; Clinical trials ; Drug therapy ; Etidronic Acid - administration &amp; dosage ; Etidronic Acid - analogs &amp; derivatives ; Etidronic Acid - therapeutic use ; Female ; Fractures ; Fractures, Bone - etiology ; Fractures, Bone - prevention &amp; control ; Humans ; Male ; Medical treatment ; Middle Aged ; Osteoporosis ; Osteoporosis, Postmenopausal - complications ; Osteoporosis, Postmenopausal - drug therapy ; Osteoporosis, Postmenopausal - epidemiology ; Pharmacology ; Raloxifene Hydrochloride - administration &amp; dosage ; Raloxifene Hydrochloride - therapeutic use ; Randomized Controlled Trials as Topic ; Risedronate Sodium ; Selective Estrogen Receptor Modulators - therapeutic use</subject><ispartof>American family physician, 2004-10, Vol.70 (7), p.1293-1300</ispartof><rights>Copyright American Academy of Family Physicians Oct 1, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15508540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zizic, Thomas M</creatorcontrib><title>Pharmacologic prevention of osteoporotic fractures</title><title>American family physician</title><addtitle>Am Fam Physician</addtitle><description>Osteoporosis is characterized by low bone mineral density and a deterioration in the microarchitecture of bone that increases its susceptibility to fracture. The World Health Organization defines osteoporosis as a bone mineral density that is 2.5 standard deviations or more below the reference mean for healthy, young white women. The prevalence of osteoporosis in black women is one half that in white and Hispanic women. In white women 50 years and older, the risk of osteoporotic fracture is nearly 40 percent over their remaining lifetime. Of the drugs that have been approved for the prevention or treatment of osteoporosis, the bisphosphonates (risedronate and alendronate) are most effective in reducing the risk of vertebral and nonvertebral fractures. Risedronate has been shown to reduce fracture risk within one year in postmenopausal women with osteoporosis and in patients with glucocorticoid-induced osteoporosis. Hormone therapy reduces fracture risk, but the benefits may not outweigh the reported risks. Teriparatide, a recombinant human parathyroid hormone, reduces the risk of new fractures and is indicated for use in patients with severe osteoporosis. Raloxifene has been shown to lower the incidence of vertebral fractures in women with osteoporosis. Salmon calcitonin is reserved for use in patients who cannot tolerate bisphosphonates or hormone therapy.</description><subject>Aged</subject><subject>Alendronate - administration &amp; dosage</subject><subject>Alendronate - therapeutic use</subject><subject>Bone Density - drug effects</subject><subject>Clinical trials</subject><subject>Drug therapy</subject><subject>Etidronic Acid - administration &amp; dosage</subject><subject>Etidronic Acid - analogs &amp; derivatives</subject><subject>Etidronic Acid - therapeutic use</subject><subject>Female</subject><subject>Fractures</subject><subject>Fractures, Bone - etiology</subject><subject>Fractures, Bone - prevention &amp; control</subject><subject>Humans</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Osteoporosis</subject><subject>Osteoporosis, Postmenopausal - complications</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Osteoporosis, Postmenopausal - epidemiology</subject><subject>Pharmacology</subject><subject>Raloxifene Hydrochloride - administration &amp; dosage</subject><subject>Raloxifene Hydrochloride - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risedronate Sodium</subject><subject>Selective Estrogen Receptor Modulators - therapeutic use</subject><issn>0002-838X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkE1LxDAYhHNQ3HX1L8jiwVsh33l7lMWPhQU9KHgr2TTRLm3fmqSC_96A68XTMMzDMMwJWVJKeQUC3hbkPKVDsUax-owsmFIUlKRLwp8_bByswx7fO7eeov_yY-5wXGNYY8oeJ4yYSxSidXmOPl2Q02D75C-PuiKv93cvm8dq9_Sw3dzuqokLmStulNTMaCsNAOPKAOUtyFap2jgfeGAajAAn5R5YG4zyDFgNYJkTQekgVuTmt3eK-Dn7lJuhS873vR09zqnRhjKopSng9T_wgHMcy7amLOFKS00LdHWE5v3g22aK3WDjd_N3hfgBfrVXfQ</recordid><startdate>20041001</startdate><enddate>20041001</enddate><creator>Zizic, Thomas M</creator><general>American Academy of Family Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20041001</creationdate><title>Pharmacologic prevention of osteoporotic fractures</title><author>Zizic, Thomas M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p234t-27546176a47881257802d84d5597cef2f168738c44b81df75e181988a1c3f56f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Alendronate - administration &amp; dosage</topic><topic>Alendronate - therapeutic use</topic><topic>Bone Density - drug effects</topic><topic>Clinical trials</topic><topic>Drug therapy</topic><topic>Etidronic Acid - administration &amp; dosage</topic><topic>Etidronic Acid - analogs &amp; derivatives</topic><topic>Etidronic Acid - therapeutic use</topic><topic>Female</topic><topic>Fractures</topic><topic>Fractures, Bone - etiology</topic><topic>Fractures, Bone - prevention &amp; control</topic><topic>Humans</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Osteoporosis</topic><topic>Osteoporosis, Postmenopausal - complications</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Osteoporosis, Postmenopausal - epidemiology</topic><topic>Pharmacology</topic><topic>Raloxifene Hydrochloride - administration &amp; dosage</topic><topic>Raloxifene Hydrochloride - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risedronate Sodium</topic><topic>Selective Estrogen Receptor Modulators - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zizic, Thomas M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>American family physician</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zizic, Thomas M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacologic prevention of osteoporotic fractures</atitle><jtitle>American family physician</jtitle><addtitle>Am Fam Physician</addtitle><date>2004-10-01</date><risdate>2004</risdate><volume>70</volume><issue>7</issue><spage>1293</spage><epage>1300</epage><pages>1293-1300</pages><issn>0002-838X</issn><coden>AFPYBF</coden><abstract>Osteoporosis is characterized by low bone mineral density and a deterioration in the microarchitecture of bone that increases its susceptibility to fracture. The World Health Organization defines osteoporosis as a bone mineral density that is 2.5 standard deviations or more below the reference mean for healthy, young white women. The prevalence of osteoporosis in black women is one half that in white and Hispanic women. In white women 50 years and older, the risk of osteoporotic fracture is nearly 40 percent over their remaining lifetime. Of the drugs that have been approved for the prevention or treatment of osteoporosis, the bisphosphonates (risedronate and alendronate) are most effective in reducing the risk of vertebral and nonvertebral fractures. Risedronate has been shown to reduce fracture risk within one year in postmenopausal women with osteoporosis and in patients with glucocorticoid-induced osteoporosis. Hormone therapy reduces fracture risk, but the benefits may not outweigh the reported risks. Teriparatide, a recombinant human parathyroid hormone, reduces the risk of new fractures and is indicated for use in patients with severe osteoporosis. Raloxifene has been shown to lower the incidence of vertebral fractures in women with osteoporosis. Salmon calcitonin is reserved for use in patients who cannot tolerate bisphosphonates or hormone therapy.</abstract><cop>United States</cop><pub>American Academy of Family Physicians</pub><pmid>15508540</pmid><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-838X
ispartof American family physician, 2004-10, Vol.70 (7), p.1293-1300
issn 0002-838X
language eng
recordid cdi_proquest_miscellaneous_67018947
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Aged
Alendronate - administration & dosage
Alendronate - therapeutic use
Bone Density - drug effects
Clinical trials
Drug therapy
Etidronic Acid - administration & dosage
Etidronic Acid - analogs & derivatives
Etidronic Acid - therapeutic use
Female
Fractures
Fractures, Bone - etiology
Fractures, Bone - prevention & control
Humans
Male
Medical treatment
Middle Aged
Osteoporosis
Osteoporosis, Postmenopausal - complications
Osteoporosis, Postmenopausal - drug therapy
Osteoporosis, Postmenopausal - epidemiology
Pharmacology
Raloxifene Hydrochloride - administration & dosage
Raloxifene Hydrochloride - therapeutic use
Randomized Controlled Trials as Topic
Risedronate Sodium
Selective Estrogen Receptor Modulators - therapeutic use
title Pharmacologic prevention of osteoporotic fractures
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T12%3A26%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacologic%20prevention%20of%20osteoporotic%20fractures&rft.jtitle=American%20family%20physician&rft.au=Zizic,%20Thomas%20M&rft.date=2004-10-01&rft.volume=70&rft.issue=7&rft.spage=1293&rft.epage=1300&rft.pages=1293-1300&rft.issn=0002-838X&rft.coden=AFPYBF&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E730025501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=234256460&rft_id=info:pmid/15508540&rfr_iscdi=true